Alert: Record-Breaking $1B Psychedelic Funding in Q2 2026

Q2 2026 witnessed unprecedented investment in the psychedelic sector, with over $1 billion raised across ten events, largely driven by Definium Therapeutics' $805M round. This significant capital influx signals robust market growth and increased confidence, which could indirectly influence future regulatory landscapes and market opportunities for compliant merchants.

The psychedelic industry experienced a record-breaking second quarter in 2026, securing over $1 billion in funding. This surge was primarily led by LSD drug developer Definium Therapeutics' massive $805M round, the largest fundraising event ever in the psychedelics field, following positive Phase 3 readouts. Other notable raises included GH Research netting $117.5M, Helus Pharma (formerly Cybin) closing a $50M raise, Optimi Health securing $15M, and Psilera announcing an $8.8M seed funding close. This strong financial activity reflects growing investor confidence and could accelerate drug development and market expansion within the psychedelic space, warranting continued monitoring by merchants.

Sentinel Insight